• 2019-07
  • 2019-08
  • 2019-09
  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • 2021-03
  • br biological differences notably access to care


    203 biological differences, notably access to care and standardized treatment, African-American
    204 Actinomycin D did not appear to be associated with inferior stage-for-stage prostate cancer-specific
    206 Americans. Our findings are in line with this report showing higher OCM rates in African-
    207 American men. In consequence, African-Americans represent a potential contemporary target
    208 for further efforts aimed at improving Actinomycin D patient selection, based on OCM criteria, as well as at
    209 identifying and addressing these competing causes of death (9).
    210 Fourth, important differences in OCM were also recorded according to marital status. Higher
    212 a fashion similar to the entire cohort, OCM rates decreased in both groups over time. The
    213 more significant decrease was recorded in unmarried men (slope: -0.29%/year). However, the
    215 consequence, unmarried patients also represent a potential contemporary target for improved
    216 patient selection based on OCM criteria.
    217 Our univariable observations pertaining to OCM rate decreases over time were corroborated
    218 in multivariable Cox regression models that tested the effect of time period, treatment type,
    219 patient age, ethnicity and marital status. Within these models, more contemporary year
    220 intervals were associated with an increasingly stronger protective effect from OCM that was
    222 Similarly, younger age category was also associated with an increasingly more protective
    225 as well as married status (HR: 0.74) were also associated with a more protective effect from
    226 OCM. All of the above variables achieved independent predictor status.
    227 Taken together, our study suggests that patient selection for either RP or EBRT may have
    228 improved over time, based on OCM criteria. Since advanced age predisposes to OCM, the
    229 most profound decrease in OCM over time was recorded in the oldest patients. Moreover,
    230 since EBRT patients are usually older than RP patients, more profound decrease in OCM was
    231 also recorded in EBRT patients. Finally, we also identified African-American ethnicity, as
    232 well as unmarried status as indicators of higher baseline OCM and of highest potential for
    233 OCM reduction over time. Even though the elderly, African-American and unmarried patients
    234 represent prime targets for improved patient selection based on OCM criteria, OCM rate
    235 improvements may still be expected in younger, Caucasian, Hispanic and married patients.
    236 Several limitations of our study need to be mentioned. First, since SEER is an observational
    237 database, data are retrospective. However, this also applies to the institutional study which
    239 regarding causes of death or comorbidities is available in the SEER-database. This
    240 information might have been of interest to evaluate over time. However, as we were assessing
    241 other-cause mortality as surrogate for life expectancy, the actual cause of death was not of
    242 specific interest. Moreover, detailed cancer-related parameters, such as prostate-specific
    243 antigen or Gleason score, were only available from 2004 onwards. Thus, detailed information
    244 on changes of PCa-related parameters, as well as potential changes in clinically localized
    245 disease stage were not assessable. Moreover, standardized staging information was not
    246 available. Similarly, staging methods and staging extent may have varied between patients
    247 over time. Additionally, we could not account for selection biases related to primary treatment